BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18087220)

  • 1. Contribution of dendritic cells' FcgammaRI and FcgammaRIII to cross-presentation of tumor cells opsonized with the anti-MHC class I monoclonal antibodies.
    Signorino E; Brusa D; Granata R; Malavasi F; Ferrone S; Matera L
    Cancer Biol Ther; 2007 Dec; 6(12):1932-7. PubMed ID: 18087220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function.
    López-Albaitero A; Mailliard R; Hackman T; Andrade Filho PA; Wang X; Gooding W; Ferrone S; Kalinski P; Ferris RL
    J Immunother; 2009 Jun; 32(5):465-73. PubMed ID: 19609238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
    Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
    Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CpG oligodeoxynucleotides enhance FcgammaRI-mediated cross presentation by dendritic cells.
    Bevaart L; Van Ojik HH; Sun AW; Sulahian TH; Leusen JH; Weiner GJ; Van De Winkel JG; Van Vugt MJ
    Int Immunol; 2004 Aug; 16(8):1091-8. PubMed ID: 15192052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells.
    Dhodapkar KM; Krasovsky J; Williamson B; Dhodapkar MV
    J Exp Med; 2002 Jan; 195(1):125-33. PubMed ID: 11781371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
    André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
    J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of drug-induced apoptotic death on processing and presentation of tumor antigens by dendritic cells.
    Buttiglieri S; Galetto A; Forno S; De Andrea M; Matera L
    Int J Cancer; 2003 Sep; 106(4):516-520. PubMed ID: 12845646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing vaccine potency using TCRmimic antibodies.
    Neethling FA; Ramakrishna V; Keler T; Buchli R; Woodburn T; Weidanz JA
    Vaccine; 2008 Jun; 26(25):3092-102. PubMed ID: 18353510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro.
    Fleischer K; Schmidt B; Kastenmüller W; Busch DH; Drexler I; Sutter G; Heike M; Peschel C; Bernhard H
    J Immunol; 2004 Jan; 172(1):162-9. PubMed ID: 14688322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exogenous antigen targeted to FcgammaRI on myeloid cells is presented in association with MHC class I.
    Wallace PK; Tsang KY; Goldstein J; Correale P; Jarry TM; Schlom J; Guyre PM; Ernstoff MS; Fanger MW
    J Immunol Methods; 2001 Feb; 248(1-2):183-94. PubMed ID: 11223078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calreticulin acts as an adjuvant to promote dendritic cell maturation and enhances antigen-specific cytotoxic T lymphocyte responses against non-small cell lung cancer cells.
    Liu X; Li J; Liu Y; Ding J; Tong Z; Liu Y; Zhou Y; Liu Y
    Cell Immunol; 2016 Feb; 300():46-53. PubMed ID: 26702740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.
    Srivastava RM; Lee SC; Andrade Filho PA; Lord CA; Jie HB; Davidson HC; López-Albaitero A; Gibson SP; Gooding WE; Ferrone S; Ferris RL
    Clin Cancer Res; 2013 Apr; 19(7):1858-72. PubMed ID: 23444227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells.
    Groh V; Li YQ; Cioca D; Hunder NN; Wang W; Riddell SR; Yee C; Spies T
    Proc Natl Acad Sci U S A; 2005 May; 102(18):6461-6. PubMed ID: 15824323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses.
    Nouri-Shirazi M; Banchereau J; Bell D; Burkeholder S; Kraus ET; Davoust J; Palucka KA
    J Immunol; 2000 Oct; 165(7):3797-803. PubMed ID: 11034385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased expression of HSP70 by colon cancer cells is not always associated with access to the dendritic cell cross-presentation pathway.
    Matera L; Forno S; Galetto A; Moro F; Garetto S; Mussa A
    Cell Mol Biol Lett; 2007; 12(2):268-79. PubMed ID: 17235439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules.
    Ramakrishna V; Treml JF; Vitale L; Connolly JE; O'Neill T; Smith PA; Jones CL; He LZ; Goldstein J; Wallace PK; Keler T; Endres MJ
    J Immunol; 2004 Mar; 172(5):2845-52. PubMed ID: 14978085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of tumor-reactive CTL against the tumor-associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoietic progenitor cells.
    Meyer zum Büschenfelde C; Nicklisch N; Rose-John S; Peschel C; Bernhard H
    J Immunol; 2000 Oct; 165(7):4133-40. PubMed ID: 11034426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells.
    Galetto A; Buttiglieri S; Forno S; Moro F; Mussa A; Matera L
    Anticancer Drugs; 2003 Nov; 14(10):833-43. PubMed ID: 14597879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
    Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
    Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells cultured in anti-CD40 antibody-immobilized plates elicit a highly efficient peptide-specific T-cell response.
    Osada T; Nagawa H; Takahashi T; Tsuno NH; Kitayama J; Shibata Y
    J Immunother; 2002; 25(2):176-84. PubMed ID: 12074047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.